top of page

Response Pharmaceuticals

Photomicrograph of RDX-002


Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002

August 17, 2023

Read more

Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company's lead drug candidate, RDX-002, a first-in-class inhibitor of intestinal microsomal triglyceride transfer protein (iMTP). While full results are being analyzed, RDX-002 was generally well tolerated, and the study met its primary objective. The company is working with its scientific team and advisory board to complete the data analysis and prepare the final full results.

Response Pharmaceuticals Closes Series A Financing 

November 21, 2022

Read more

Response Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $8 million financing round. Response Pharmaceuticals is a clinical-stage therapeutic development company focused on developing innovative treatments for weight management and metabolic disease. The company's lead drug candidate, RDX-002, a first-in-class inhibitor of enterocytic microsomal triglyceride transfer protein (eMTP) originally conceived and developed by the company’s CSO and Co-Founder, Paul Sweetnam, is being studied for Antipsychotic Induced Weight Gain (AIWG), a common and potentially harmful side effect of antipsychotic medication. eMTP is a protein believed to be a key driver of weight gain in patients on antipsychotic drugs. In prior clinical studies, RDX-002 has generated data in over 500 human subjects across 7 clinical trials to date.

bottom of page